Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials
Open accessAbstract
Protein–protein interactions (PPIs) have pivotal roles in life processes. The studies showed that aberrant PPIs are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. Therefore, targeting PPIs is a direction in treating diseases and an essential strategy for the development of new drugs. In the past few decades, the modulation of PPIs has been recognized as one of the most challenging drug discovery tasks. In recent years, some PPIs modulators have entered clinical studies, some of which been approved for marketing, indicating that the modulators targeting PPIs have broad prospects. Here, we summarize the recent advances in PPIs modulators, including small molecules, peptides, and antibodies, hoping to provide some guidance to the design of novel drugs targeting PPIs in the future.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Peptides and proteins have general physicochemical properties, such as instability under physiological conditions, poor oral bioavailability and solubility, which make them less optimal drugs.
“However, peptides and proteins have general physicochemical properties, such as instability under physiological conditions, poor oral bioavailability and solubility, which make them less optimal drugs.19”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [19]
YAP/TAZ and β-catenin belong to TFs that have traditionally been considered "undruggable" targets.
“Among them, YAP/TAZ and β-catenin belong to TFs have traditionally been considered “undruggable” targets.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [19]
There are several other undruggable proteins that can be regulated by PPI modulation, such as YAP/TAZ, β-catenin, XIAP, etc.
“There are several other undruggable proteins can be regulated by PPI modulation, such as YAP/TAZ, β-catenin, XIAP, etc.19”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,484 · see citing works
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101 · see citing works
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593 · see citing works
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1317 · Cited by 4,534 · see citing works
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032 · see citing works
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733 · see citing works
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407 · see citing works
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390 · see citing works
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,177 · see citing works
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114 · see citing works
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · see citing works
Towards a proteome-scale map of the human protein–protein interaction network
Rual, J.-F. M., Venkatesan, K., Hao, T., Hirozane-Kishikawa, T., Dricot, A., Li, N., Berriz, G. F., Gibbons, F. D., Dreze, M., Ayivi-Guedehoussou, N., et al. (2005) · Nature · doi:10.1038/nature04209 · Cited by 2,937 · see citing works
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427 · see citing works
A Human Protein-Protein Interaction Network: A Resource for Annotating the Proteome
Stelzl, U., Worm, U., Lalowski, M. M., Haenig, C., Brembeck, F. H., Goehler, H., Strödicke, M., Zenkner, M., Schoenherr, A., Koeppen, S., et al. (2005) · Cell · doi:10.1016/j.cell.2005.08.029 · Cited by 2,389 · see citing works
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312 · see citing works
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · see citing works
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992 · see citing works
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,963 · see citing works
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · see citing works
IAP proteins: blocking the road to death's door
Salvesen, G. S., & Duckett, C. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm830 · Cited by 1,756 · see citing works
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · see citing works
Molecular mechanism and function of CD40/CD40L engagement in the immune system
Elgueta, R., Benson, M. J., de Vries, V. C., Wasiuk, A., Guo, Y., & Noelle, R. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00782.x · Cited by 1,633 · see citing works
14-3-3 Proteins: Structure, Function, and Regulation
Fu, H., Subramanian, R. R., & Masters, S. C. (2000) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.617 · Cited by 1,569 · see citing works
Schopf, F. H., Biebl, M. M., & Buchner, J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.20 · Cited by 1,540 · see citing works
Structure of the Cul1–Rbx1–Skp1–F boxSkp2 SCF ubiquitin ligase complex
Zheng, N., Schulman, B. A., Song, L., Miller, J. J., Jeffrey, P. D., Wang, P., Chu, C., Koepp, D. M., Elledge, S. J., Pagano, M., et al. (2002) · Nature · doi:10.1038/416703a · Cited by 1,507 · see citing works
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,489 · see citing works
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martínez, J., & Khrestchatisky, M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,487 · see citing works
Donato, R., Cannon, B. R., Sorci, G., Riuzzi, F., Hsu, K., Weber, D. J., & Geczy, C. L. (2012) · Current Molecular Medicine · doi:10.2174/156652413804486214 · Cited by 1,319 · see citing works
Dorr, P. K., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M. J., Mori, J., Rickett, G., Smith‐Burchnell, C., Napier, C. M., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,154 · see citing works
Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137 · see citing works
Structure and mechanism of the Hsp90 molecular chaperone machinery
Pearl, L. H., & Prodromou, C. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142738 · Cited by 1,103 · see citing works
Mechanistic Studies of the Nrf2-Keap1 Signaling Pathway
Zhang, D. D. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600971974 · Cited by 1,091 · see citing works
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,068 · see citing works
Srinivasula, S. M., Hegde, R. P., Saleh, A., Datta, P., Shiozaki, E. N., Chai, J., Lee, R., Robbins, P. D., Fernandes‐Alnemri, T., Shi, Y., et al. (2001) · Nature · doi:10.1038/35065125 · Cited by 1,013 · see citing works
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 960 · see citing works
An empirical framework for binary interactome mapping
Venkatesan, K., Rual, J.-F. M., Vázquez, A., Stelzl, U., Lemmens, I. H., Hirozane-Kishikawa, T., Hao, T., Zenkner, M., Xin, X., Goh, K. I., et al. (2008) · Nature Methods · doi:10.1038/nmeth.1280 · Cited by 907 · see citing works
Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer
Frescas, D., & Pagano, M. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2396 · Cited by 886 · see citing works
Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition
Taipale, M., Krykbaeva, I., Koeva, M., Kayatekin, C., Westover, K. D., Karras, G. I., & Lindquist, S. (2012) · Cell · doi:10.1016/j.cell.2012.06.047 · Cited by 879 · see citing works
Structural and biochemical basis of apoptotic activation by Smac/DIABLO
Chai, J., Du, C., Wu, J.-W., Kyin, S., Wang, X., & Shi, Y. (2000) · Nature · doi:10.1038/35022514 · Cited by 864 · see citing works
Structural basis of IAP recognition by Smac/DIABLO
Wu, G., Chai, J., Suber, T. L., Wu, J., Du, C., Wang, X., & Shi, Y. (2000) · Nature · doi:10.1038/35050012 · Cited by 863 · see citing works
Miller, D. M., Thomas, S. D., Islam, A., Muench, D. E., & Sedoris, K. C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0977 · Cited by 844 · see citing works
14-3-3 proteins: A historic overview
Aitken, A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.03.005 · Cited by 829 · see citing works
Estimating the size of the human interactome
Stumpf, M. P. H., Thorne, T., de Silva, E., Stewart, R., An, H. J., Lappé, M., & Wiuf, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708078105 · Cited by 827 · see citing works
Rees, D. C., Congreve, M., Murray, C. W., & Carr, R. A. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1467 · Cited by 797 · see citing works
IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
Gyrd-Hansen, M., & Meier, P. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2889 · Cited by 790 · see citing works
Magesh, S., Chen, Y., & Hu, L. (2012) · Medicinal Research Reviews · doi:10.1002/med.21257 · Cited by 760 · see citing works
Hot spots—A review of the protein–protein interface determinant amino‐acid residues
Moreira, I. S., Fernandes, P. A., & Ramos, M. J. (2007) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21396 · Cited by 760 · see citing works
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 760 · see citing works
Dirix, L. Y., Takács, I., Jérusalem, G., Nikolinakos, P. G., Arkenau, H., Forero, A., Boccia, R. V., Lippman, M. E., Somer, R. A., Šmakal, M., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 748 · see citing works
Structural biology of the Bcl-2 family of proteins
Petros, A. M., Olejniczak, E. T., & Fesik, S. W. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2003.08.012 · Cited by 745 · see citing works
Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer
Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735 · see citing works
Mechanism of XIAP-Mediated Inhibition of Caspase-9
Shiozaki, E. N., Chai, J., Rigotti, D. J., Riedl, S. J., Li, P., Srinivasula, S. M., Alnemri, E. S., Fairman, R., & Shi, Y. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00054-6 · Cited by 718 · see citing works
Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702 · see citing works
Alushin, G. M., Lander, G. C., Kellogg, E. H., Zhang, R., Baker, D., & Nogales, E. (2014) · Cell · doi:10.1016/j.cell.2014.03.053 · Cited by 696 · see citing works
Structure-based maximal affinity model predicts small-molecule druggability
Cheng, A. C., Coleman, R. G., Smyth, K. T., Cao, Q., Soulard, P., Caffrey, D. R., Salzberg, A. C., & Huang, E. S. (2007) · Nature Biotechnology · doi:10.1038/nbt1273 · Cited by 694 · see citing works
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
Kawai, T., Andrews, D. M., Colvin, R. B., Sachs, D. H., & Cosimi, A. B. (2000) · Nature Medicine · doi:10.1038/72162 · Cited by 693 · see citing works
Mechanisms and function of substrate recruitment by F-box proteins
Skaar, J. R., Pagan, J. K., & Pagano, M. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3582 · Cited by 671 · see citing works
Chang, Y. S., Graves, B. J., Guerlavais, V., Tovar, C., Packman, K. E., To, K.-H., Olson, K. A., Kesavan, K. P., Gangurde, P., Mukherjee, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303002110 · Cited by 666 · see citing works
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · see citing works
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623 · see citing works
14-3-3 proteins in the nervous system
Berg, D., Holzmann, C., & Rieß, O. (2003) · Nature reviews. Neuroscience · doi:10.1038/nrn1197 · Cited by 619 · see citing works
Boumpas, D. T., Furie, R. A., Manzi, S., Illei, G. G., Wallace, D. J., Balow, J. E., Vaishnaw, A. K., & on behalf of the BG9588 Lupus Nephritis Trial Group (2003) · Arthritis & Rheumatism · doi:10.1002/art.10856 · Cited by 617 · see citing works
Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling
Lo, S., Li, X., Henzl, M. T., Beamer, L. J., & Hannink, M. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601243 · Cited by 604 · see citing works
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596 · see citing works
Heat shock protein 90 as a molecular target for cancer therapeutics
Isaacs, J. S., Xu, W., & Neckers, L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00029-1 · Cited by 575 · see citing works
Buckley, D. L., Van Molle, I., Gareiss, P. C., Tae, H. S., Michel, J., Noblin, D. J., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja209924v · Cited by 569 · see citing works
The inhibitors of apoptosis (IAPs) as cancer targets
Hunter, A. M., LaCasse, E. C., & Korneluk, R. G. (2007) · Apoptosis · doi:10.1007/s10495-007-0087-3 · Cited by 565 · see citing works
Rudin, C. M., Hann, C. L., Garon, E. B., de Oliveira, M. R., Bonomi, P., Camidge, D. R., Chu, Q. S.-C., Giaccone, G., Khaira, D. K., Ramalingam, S. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3090 · Cited by 563 · see citing works
X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA
Nair, S. K., & Burley, S. K. (2003) · Cell · doi:10.1016/s0092-8674(02)01284-9 · Cited by 551 · see citing works
Wandinger, S. K., Richter, K., & Büchner, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800007200 · Cited by 548 · see citing works
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Żak, K. M., Kitel, R., Przetocka, S., Golik, P., Guzik, K., Musielak, B., Dömling, A. S. S., Dubin, G., & Holak, T. A. (2015) · Structure · doi:10.1016/j.str.2015.09.010 · Cited by 541 · see citing works
K-ras is an essential gene in the mouse with partial functional overlap with N-rasPreprint
Johnson, L., Greenbaum, D. C., Cichowski, K. M., Mercer, K. L., Murphy, E. A., Schmitt, E. S., Bronson, R. T., Umanoff, H., Edelmann, W., Kucherlapati, R., et al. (1997) · Genes & Development · doi:10.1101/gad.11.19.2468 · Cited by 540 · see citing works
MYC: Connecting selective transcriptional control to global RNA production
Kress, T. R., Sabò, A., & Amati, B. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3984 · Cited by 521 · see citing works
Portela, A., & Digard, P. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-4-723 · Cited by 515 · see citing works
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Dermani, F. K., Samadi, P., Rahmani, G., Kohlan, A. K., & Najafi, R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27172 · Cited by 509 · see citing works
The Hsp90 chaperone machinery: Conformational dynamics and regulation by co-chaperones
Li, J., Soroka, J., & Buchner, J. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.09.003 · Cited by 498 · cited 1× · see citing works
“which regulate the cancer cell’s growth and apoptosis signaling pathways.(105,106) Hsp90 stabilizes the conformation of the client proteins mentioned above and prevents them from ubiquitination-mediated degradation, thereby stabilizes them to stay in the active form and promotes the tumor growth and metastasis (Fig.”
BackgroundModulators of Protein–Protein Interactions
Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497 · see citing works
Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents
Prota, A. E., Bargsten, K., Zurwerra, D., Field, J. J., Díaz, J. F., Altmann, K., & Steinmetz, M. O. (2013) · Science · doi:10.1126/science.1230582 · Cited by 494 · see citing works
Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis
Sabò, A., Kress, T. R., Pelizzola, M., de Pretis, S., Gorski, M. M., Tesi, A., Morelli, M. J., Bora, P., Doni, M., Verrecchia, A., et al. (2014) · Nature · doi:10.1038/nature13537 · Cited by 478 · see citing works
Boyerinas, B., Jochéms, C., Fantini, M. C., Heery, C. R., Gulley, J. L., Tsang, K. Y., & Schlom, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0059 · Cited by 468 · see citing works
Clinical targeting of the TNF and TNFR superfamilies
Croft, M., Benedict, C. A., & Ware, C. F. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3930 · Cited by 457 · see citing works
The Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447 · see citing works
Microtubules and Their Role in Cellular Stress in Cancer
Parker, A. L., Kavallaris, M., & McCarroll, J. A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00153 · Cited by 443 · see citing works
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 433 · see citing works
Many players in BCL-2 family affairs
Moldoveanu, T., Follis, A. V., Kriwacki, R. W., & Green, D. R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.006 · Cited by 421 · see citing works
Constraining Cyclic Peptides To Mimic Protein Structure Motifs
Hill, T. A., Shepherd, N. E., Diness, F., & Fairlie, D. P. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201401058 · Cited by 418 · see citing works
Structural basis for protein–protein interactions in the 14-3-3 protein family
Yang, X., Lee, W. H., Sobott, F., Papagrigoriou, E., Robinson, C. V., Grossmann, J. G., Sundström, M., Doyle, D., & Elkins, J. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605779103 · Cited by 415 · see citing works
Thorn, K. S., & Bogan, A. A. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.3.284 · Cited by 403 · see citing works
Targeting protein–protein interactions as an anticancer strategy
Ivanov, A. A., Khuri, F. R., & Fu, H. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.007 · Cited by 401 · see citing works
Blocking of the PD‐1/PD‐L1 Interaction by a D ‐Peptide Antagonist for Cancer Immunotherapy
Chang, H., Liu, B., Qi, Y., Zhou, Y., Chen, Y., Pan, K., Li, W., Zhou, X., Ma, W., Fu, C., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506225 · Cited by 401 · see citing works
Protein–protein interaction and quaternary structure
Janin, J., Bahadur, R. P., & Chakrabarti, P. (2008) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004708 · Cited by 400 · see citing works
Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development
Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395 · see citing works
Chan, C.-H., Morrow, J. K., Li, C.-F., Gao, Y., Jin, G., Moten, A., Stagg, L. J., Ladbury, J. E., Cai, Z., Xu, D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.048 · Cited by 391 · see citing works
Targeting the MDM2-p53 Interaction for Cancer Therapy
Shangary, S. K., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 364 · see citing works
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
Vogler, M., Dinsdale, D. D., Dyer, M. J. S., & Cohen, G. M. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.137 · Cited by 359 · see citing works
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox, A. D., Der, C. J., & Philips, M. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3214 · Cited by 351 · see citing works
The Mechanism of Hsp90 Regulation by the Protein Kinase-Specific Cochaperone p50cdc37
Roe, S. M., Ali, M. M. U., Meyer, P., Vaughan, C. K., Panaretou, B., Piper, P. W., Prodromou, C., & Pearl, L. H. (2004) · Cell · doi:10.1016/s0092-8674(03)01027-4 · Cited by 351 · see citing works
SCF ubiquitin ligase-targeted therapies
Skaar, J. R., Pagan, J. K., & Pagano, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4432 · Cited by 336 · see citing works
Chandra, A., Grecco, H. E., Pisupati, V., Perera, D., Cassidy, L., Skoulidis, F., Ismail, S. A., Hedberg, C., Hanzal-Bayer, M., Venkitaraman, A. R., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2394 · Cited by 325 · see citing works
Davies, T. G., Wixted, W. E., Coyle, J. E., Griffiths-Jones, C., Hearn, K., McMenamin, R., Norton, D., Rich, S. J., Richardson, C., Saxty, G., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00228 · Cited by 322 · see citing works
Specific Patterns of Electrophile Adduction Trigger Keap1 Ubiquitination and Nrf2 Activation
Hong, F., Sekhar, K. R., Freeman, M. L., & Liebler, D. C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503346200 · Cited by 316 · see citing works
Oncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312 · see citing works
Mirguet, O., Gosmini, R. L., Toum, J., Clément, C. A., Barnathan, M., Brusq, J.-M. G., Mordaunt, J. E., Grimes, R. M., Crowe, M. C., Pineau, O., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401088k · Cited by 310 · see citing works
14-3-3 proteins in cell cycle regulation
Hermeking, H., & Benzinger, A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.03.002 · Cited by 307 · see citing works
Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α
Buckley, D. L., Gustafson, J. L., Van Molle, I., Roth, A. G., Tae, H. S., Gareiss, P. C., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206231 · Cited by 302 · see citing works
Mhawech, P. (2005) · Cell Research · doi:10.1038/sj.cr.7290291 · Cited by 302 · see citing works
Park, C., Bruncko, M., Adickes, J., Bauch, J. L., Ding, H., Kunzer, A. R., Marsh, K. C., Nimmer, P. M., Shoemaker, A. R., Song, X., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800669s · Cited by 301 · see citing works
Assessing Helical Protein Interfaces for Inhibitor Design
Bullock, B. N., Jochim, A. L., & Arora, P. S. (2011) · Journal of the American Chemical Society · doi:10.1021/ja206074j · Cited by 298 · see citing works
Modulating protein–protein interactions: the potential of peptides
Nevola, L., & Giralt, E. (2014) · Chemical Communications · doi:10.1039/c4cc08565e · Cited by 291 · see citing works
Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401753e · Cited by 290 · see citing works
Smith, M. C. P., & Gestwicki, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.10 · Cited by 285 · see citing works
Jiang, Z., Lu, M., Xu, L., Yang, T., Xi, M., Xu, X., Guo, X., Zhang, X., You, Q., & Sun, H.-P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5000529 · Cited by 263 · see citing works
Self-citationOttmann, C., Marco, S., Jaspert, N., Marcon, C., Schauer, N., Weyand, M., Vandermeeren, C., Duby, G., Boutry, M., Wittinghofer, A., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.12.017 · Cited by 255 · see citing works
Flygare, J. A., Beresini, M., Budha, N., Chan, H., Chan, I. T., Cheeti, S., Cohen, F., Deshayes, K., Doerner, K., Eckhardt, S. G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300060k · Cited by 252 · see citing works
Development and application of Hsp90 inhibitors
Solit, D. B., & Chiosis, G. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.007 · Cited by 251 · see citing works
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Carvajal, L. A., Neriah, D. B., Senecal, A., Benard, L., Thiruthuvanathan, V., Yatsenko, T., Narayanagari, S.-R., Wheat, J. C., Todorova, T. I., Mitchell, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao3003 · Cited by 249 · see citing works
Marcotte, D. J., Zeng, W., Hus, J., McKenzie, A., Hession, C., Jin, P., Bergeron, C., Lugovskoy, A. A., Enyedy, I. J., Cuervo, H., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.019 · Cited by 245 · see citing works
Schmick, M., Vartak, N., Papke, B., Kovacevic, M., Truxius, D. C., Rossmannek, L., & Bastiaens, P. I. H. (2014) · Cell · doi:10.1016/j.cell.2014.02.051 · Cited by 243 · see citing works
Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics
Πέττα, Ι., Lievens, S., Libert, C., Tavernier, J. H., & Bosscher, K. D. (2015) · Molecular Therapy · doi:10.1038/mt.2015.214 · Cited by 240 · see citing works
Bailey, D., Jahagirdar, R., Gordon, A., Hafiane, A., Campbell, S., Chatur, S., Wagner, G. S., Hansen, H. C., Chiacchia, F. S., Johansson, J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.035 · Cited by 233 · see citing works
Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology
Shiozaki, E. N., & Shi, Y. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.07.003 · Cited by 233 · see citing works
Multiple Independent Binding Sites for Small-Molecule Inhibitors on the Oncoprotein c-Myc
Hammoudeh, D. I., Follis, A. V., Prochownik, E. V., & Metallo, S. J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja900616b · Cited by 232 · see citing works
Mechanism of the Nrf2/Keap1/ARE signaling system
Tkachev, V., Брониславовна, М. Е., & Зенков, Н. К. (2011) · Biochemistry (Moscow) · doi:10.1134/s0006297911040031 · Cited by 228 · see citing works
Killing cancer cells by flipping the Bcl-2/Bax switch
Cory, S., & Adams, J. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.012 · Cited by 217 · see citing works
Low-dielectric-constant polyimide aerogel composite films with low water uptake
Kim, J., Kwon, J., Kim, M., Do, J., Lee, D., & Han, H. (2016) · Polymer Journal · doi:10.1038/pj.2016.37 · Cited by 211 · see citing works
Analyzing Protein–Protein Interaction Networks
Koh, G. C. K. W., Porras, P., Aranda, B., Hermjakob, H., & Orchard, S. E. (2012) · Journal of Proteome Research · doi:10.1021/pr201211w · Cited by 209 · see citing works
Thiel, P., Kaiser, M., & Ottmann, C. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201107616 · Cited by 207 · see citing works
Sintilimab: First Global Approval
Hoy, S. M. (2019) · Drugs · doi:10.1007/s40265-019-1066-z · Cited by 207 · see citing works
Discovery of a small-molecule inhibitor and cellular probe of Keap1–Nrf2 protein–protein interaction
Hu, L., Magesh, S., Chen, L., Wang, L., Lewis, T. A., Chen, Y., Khodier, C., Inoyama, D., Beamer, L. J., Emge, T. J., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.013 · Cited by 206 · see citing works
Holzer, P., Masuya, K., Furet, P., Kallen, J., Valat-Stachyra, T., Ferretti, S., Berghausen, J., Bouisset-Leonard, M., Buschmann, N., Pissot-Soldermann, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00810 · Cited by 203 · see citing works
Library Design for Fragment Based Screening
Schuffenhauer, A., Rüdisser, S., Marzinzik, A. L., Jahnke, W., Selzer, P. M., & Jacoby, E. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026054637700 · Cited by 203 · see citing works
Cummins, J. M., Kohli, M., Rago, C., Kinzler, K. W., Vogelstein, B., & Bunz, F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0046 · Cited by 200 · see citing works
Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease
Perez, V. L., Pflugfelder, S. C., Zhang, S., Shojaei, A., & Haque, R. M. (2016) · The Ocular Surface · doi:10.1016/j.jtos.2016.01.001 · Cited by 200 · see citing works
Terphenyl-Based Bak BH3 α-Helical Proteomimetics as Low-Molecular-Weight Antagonists of Bcl-x L
Yin, H. H., Lee, G.-I., Sedey, K. A., Kutzki, O., Park, H. S., Orner, B. P., Ernst, J. T., Wang, H., Sebti, S. M., & Hamilton, A. D. (2005) · Journal of the American Chemical Society · doi:10.1021/ja050122x · Cited by 199 · see citing works
Blazer, L. L., & Neubig, R. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.151 · Cited by 197 · see citing works
Arkin, M. R., & Whitty, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.05.125 · Cited by 190 · see citing works
Chung, C., Dean, A. W., Woolven, J. M., & Bamborough, P. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201320w · Cited by 188 · see citing works
Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer
Hershko, D. (2008) · Cancer · doi:10.1002/cncr.23317 · Cited by 186 · see citing works
Follis, A. V., Hammoudeh, D. I., Wang, H., Prochownik, E. V., & Metallo, S. J. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.09.011 · Cited by 183 · see citing works
Benetatos, C. A., Mitsuuchi, Y., Burns, J. M., Neiman, E. M., Condon, S. M., Yu, G., Seipel, M. E., Kapoor, G. S., LaPorte, M. G., Rippin, S. R., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0798 · Cited by 179 · see citing works
The Nrf2-Keap1-ARE Signaling Pathway: The Regulation and Dual Function of Nrf2 in Cancer
Zhang, D. D. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3301 · Cited by 177 · see citing works
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy
Porter, J. R., Fritz, C., & Depew, K. M. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.019 · Cited by 177 · see citing works
Schneider, M., Hansen, J. L., & Sheikh, S. P. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0301-3 · Cited by 173 · see citing works
CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?
Musielak, B., Kocik-Krol, J., Skalniak, Ł., Magiera‐Mularz, K., Sala, D., Czub, M., Stec, M., Siedlar, M., Holak, T. A., & Plewka, J. (2019) · Molecules · doi:10.3390/molecules24152804 · Cited by 171 · see citing works
Lu, S., Shen, Q., & Zhang, J. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00570 · Cited by 166 · see citing works
State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors
Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00252d · Cited by 165 · see citing works
Ottmann, C., Yasmin, L., Weyand, M., Veesenmeyer, J. L., Diaz, M. H., Palmer, R. H., Francis, M. S., Hauser, A. R., Wittinghofer, A., & Hallberg, B. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601530 · Cited by 164 · see citing works
Zhang, H., Li, S., Doan, T. A., Rieke, F. M., Detwiler, P. B., Frederick, J. M., & Baehr, W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701681104 · Cited by 160 · see citing works
Design and Development of Peptides and Peptide Mimetics as Antagonists for Therapeutic Intervention
Mason, J. M. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.259 · Cited by 160 · see citing works
Zhuang, C., Narayanapillai, S. C., Zhang, W., Sham, Y. Y., & Xing, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017174 · Cited by 156 · see citing works
The Charged Linker Region Is an Important Regulator of Hsp90 Function*
Hainzl, O., Lapina, M. C., Buchner, J., & Richter, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.031658 · Cited by 150 · see citing works
S100 protein family and its application in clinical practice.
Sedaghat, F., & Νοτόπουλος, Α. (2008) · PubMed · Cited by 150 · see citing works
Allen, J. G., Bourbeau, M. P., Wohlhieter, G. E., Bartberger, M. D., Michelsen, K., Hungate, R. W., Gadwood, R. C., Gaston, R. D., Evans, B., Mann, L. W., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900681h · Cited by 148 · see citing works
Peptide inhibitors of the Keap1–Nrf2 protein–protein interaction
Hancock, R., Bertrand, H. C., Tsujita, T., Naz, S., El-Bakry, A., Laoruchupong, J., Hayes, J. D., & Wells, G. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.486 · Cited by 147 · see citing works
Anticancer Inhibitors of Hsp90 Function
Garg, G., Khandelwal, A., & Blagg, B. S. J. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2015.12.001 · Cited by 147 · see citing works
Rajan, A., Kelly, R. J., Trepel, J. B., Kim, Y. S., Alarcon, S. V., Kummar, S., Gutierrez, M. E., Crandon, S. K., Zein, W. M., Jain, L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0821 · Cited by 146 · see citing works
An update of the S100 nomenclature
Marenholz, I., Lovering, R. C., & Heizmann, C. W. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.07.013 · Cited by 140 · see citing works
Gerritz, S. W., Cianci, C., Kim, S., Pearce, B. C., Deminie, C. A., Discotto, L. F., McAuliffe, B. V., Minassian, B., Shi, S., Zhu, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107906108 · Cited by 140 · see citing works
Mutational spectrum of p53 mutations in primary breast and ovarian tumors
Feki, A., & Irminger-Finger, I. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.07.002 · Cited by 139 · see citing works
Targeting the oncogene and kinome chaperone CDC37
Gray, P. J., Prince, T. L., Cheng, J., Stevenson, M. A., & Calderwood, S. K. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2420 · Cited by 136 · see citing works
Buchwald, P. (2010) · IUBMB Life · doi:10.1002/iub.383 · Cited by 133 · cited 1× · see citing works
“Besides, compared to traditional small molecule drugs (200–500 Da), drugs acting on PPIs have a higher molecular weight (>400 Da), which makes it challenging to meet the criteria like Lipinski’s “rule of 5”.(23,27)”
BackgroundThe CD40-CD40L system in cardiovascular disease
Pamukçu, B., Lip, G. Y. H., Snezhitskiy, V. А., & Shantsila, E. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.546362 · Cited by 132 · see citing works
Castell, A., Yan, Q., Fawkner, K., Hydbring, P., Zhang, F., Verschut, V., Franco, M., Zakaria, S. M., Bazzar, W., Goodwin, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28107-4 · Cited by 126 · see citing works
Bertrand, H. C., Schaap, M., Baird, L., Georgakopoulos, N., Fowkes, A., Thiollier, C., Kaatchi, H., Dinkova‐Kostova, A. T., & Wells, G. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00602 · Cited by 123 · see citing works
Protein–protein interactions as targets for small-molecule therapeutics in cancer
White, A. W., Westwell, A. D., & Brahemi, G. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000641 · Cited by 122 · see citing works
Characteristics, Properties and Analytical Methods of Paclitaxel: A Review
Alves, R. C., Fernandes, R. P., Eloy, J. O., Salgado, H. R. N., & Chorilli, M. (2017) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2017.1416283 · Cited by 118 · see citing works
Paoluzzi, L., Gönen, M., Bhagat, G., Furman, R. R., Gardner, J. R., Scotto, L., Gueorguiev, V. D., Heaney, M. L., Manova, K., & O’Connor, O. A. (2008) · Blood · doi:10.1182/blood-2007-12-130781 · Cited by 117 · see citing works
Lugovskoy, A. A., Degterev, A., Fahmy, A. F., Zhou, P., Gross, J. D., Yuan, J., & Wagner, G. (2002) · Journal of the American Chemical Society · doi:10.1021/ja011239y · Cited by 116 · see citing works
Winter, A., Higueruelo, A. P., Marsh, M., Sigurdardottir, A., Pitt, W. R., & Blundell, T. L. (2012) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583512000108 · Cited by 115 · see citing works
Mullard, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4545 · Cited by 113 · see citing works
Byrd, J. C., Kipps, T. J., Flinn, I. W., Cooper, M., Odenike, O. M., Bendiske, J., Rediske, J. J., Bilic, S., Dey, J., Baeck, J., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.681655 · Cited by 112 · see citing works
Kimura, K., Ikoma, A., Shibakawa, M., Shimoda, S., Harada, K., Saio, M., Imamura, J., Osawa, Y., Kimura, M., Nishikawa, K., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.08.016 · Cited by 112 · see citing works
Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes
Wagner, D. H., Vaitaitis, G. M., Sanderson, R. J., Poulin, M., Dobbs, C. M., & HASKINS, K. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052247099 · Cited by 112 · see citing works
Mdm2 and MdmX partner to regulate p53
Wang, X., & Jiang, X. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.02.049 · Cited by 111 · see citing works
Anti-inflammatory Effect of a Cell-Penetrating Peptide Targeting the Nrf2/Keap1 Interaction
Steel, R., Cowan, J., Payerne, E., O'Connell, M. A., & Searcey, M. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300041g · Cited by 111 · see citing works
Silvestre, H. L., Blundell, T. L., Abell, C., & Ciulli, A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304045110 · Cited by 109 · see citing works
Disruption of protein–protein interactions: Towards new targets for chemotherapy
Loregian, A., & Palù, G. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20356 · Cited by 108 · see citing works
Lehmann, C. H. K., Friess, T., Birzele, F., Kiialainen, A., & Dangl, M. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0280-3 · Cited by 106 · see citing works
Hot-spot analysis for drug discovery targeting protein-protein interactions
Rosell, M., & Fernández-Recio, J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1430763 · Cited by 105 · see citing works
Inoyama, D., Chen, Y., Huang, X., Beamer, L. J., Kong, A. T., & Hu, L. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111430124 · Cited by 101 · see citing works
Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment
Patel, H., Modi, S., Chiosis, G., & Taldone, T. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.563296 · Cited by 101 · see citing works
Alternative modulation of protein–protein interactions by small molecules
Fischer, G., Rossmann, M., & Hyvönen, M. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2015.04.006 · Cited by 97 · see citing works
p53 α-Helix mimetics antagonize p53/MDM2 interaction and activate p53
Chen, L., Yin, H. H., Farooqi, B., Sebti, S. M., Hamilton, A. D., & Chen, J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0342 · Cited by 97 · see citing works
Jiang, Z., Xu, L., Lu, M., Chen, Z., Yuan, Z., Xu, X., Guo, X., Zhang, X., Sun, H.-P., & You, Q. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00185 · Cited by 94 · see citing works
Self-citationHancock, R., Schaap, M., Pfister, H., & Wells, G. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob40249e · Cited by 91 · see citing works
de Vega, M. J. P., Martín‐Martinez, M., & González‐Muñiz, R. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607779318325 · Cited by 90 · see citing works
Martín‐Gago, P., Fansa, E. K., Klein, C. H., Murarka, S., Janning, P., Schürmann, M., Metz, M., Ismail, S., Schultz‐Fademrecht, C., Baumann, M., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610957 · Cited by 89 · see citing works
Structure of Ca2+-Bound S100A4 and Its Interaction with Peptides Derived from Nonmuscle Myosin-IIA
Malashkevich, V. N., Varney, K. M., Garrett-Thomson, S. C., Wilder, P. T., Knight, D. P., Charpentier, T. H., Ramagopal, U. A., Almo, S. C., Weber, D. J., & Bresnick, A. R. (2008) · Biochemistry · doi:10.1021/bi702537s · Cited by 89 · see citing works
Field, J. J., Singh, A. J., Kanakkanthara, A., Halafihi, T., Northcote, P. T., & Miller, J. H. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901249g · Cited by 87 · see citing works
Structure, Function, Involvement in Diseases and Targeting of 14-3-3 Proteins: An Update
Cau, Y., Valensin, D., Mori, M., Draghi, S., & Botta, M. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170426095015 · Cited by 87 · see citing works
The concept of allosteric modulation: an overview
Changeux, J. (2012) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2012.07.007 · Cited by 86 · see citing works
Drugging challenging targets using fragment-based approaches
Coyne, A. G., Scott, D. E., & Abell, C. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.010 · Cited by 86 · see citing works
Flagged first, then by citations
1 of the 272 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- [1]Ferrari, S., Pellati, F. & Costi, M. P. Disruption of Protein-Protein Interfaces (Springer, Berlin, 2013).
- [71]Chen L P53 alpha-helix mimetics antagonize p53/MDM2 interaction and activate p53 Mol. Cancer Therap. 2005 4 1019 1025 10.1158/1535-7163.MCT-04-0342 15956260 · DOI
Cited by
Sorted by citations
Gene regulatory network inference in the era of single-cell multi-omics
Badia-i-Mompel, P., Wessels, L., Müller‐Dott, S., Trimbour, R., Flores, R. O. R., Argelaguet, R., & Sáez-Rodríguez, J. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00618-5 · Cited by 475 · see citing works
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449 · see citing works
Self-citationRecent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Self-citationMYC protein interactors in gene transcription and cancer
Lourenco, C., Resetca, D., Redel, C., Lin, P., MacDonald, A. S., Ciaccio, R., Kenney, T. M. G., Wei, Y., Andrews, D. W., Sunnerhagen, M., et al. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00367-9 · Cited by 341 · see citing works
PLIP 2025: introducing protein–protein interactions to the protein–ligand interaction profiler
Schake, P., Bolz, S. N., Linnemann, K. L., & Schroeder, M. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf361 · Cited by 348 · see citing works
New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Nada, H., Choi, Y., Kim, S.-D., Jeong, K. S., Meanwell, N. A., & Lee, K. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02036-3 · Cited by 233 · see citing works
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Ahmadi, S. E., Rahimi, S., Zarandi, B., Chegeni, R., & Safa, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01111-4 · Cited by 211 · see citing works
Beck, H., Härter, M. W., Haß, B., Schmeck, C., & Bärfacker, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.015 · Cited by 201 · see citing works
Protein–protein interaction prediction with deep learning: A comprehensive review
Soleymani, F., Paquet, E., Viktor, H. L., Michalowski, W. J., & Spinello, D. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.08.070 · Cited by 195 · see citing works
Current Advances in RNA Therapeutics for Human Diseases
Zogg, H., Singh, R., & Ro, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052736 · Cited by 173 · see citing works
PHI-base in 2022: a multi-species phenotype database for Pathogen–Host Interactions
Urban, M., Cuzick, A., Seager, J. W., Wood, V., Rutherford, K., Venkatesh, S. Y., Sahu, J., Iyer, S. V., Khamari, L., Silva, N. H. D., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1037 · Cited by 166 · see citing works
Recent advances in the development of therapeutic peptides
Fetse, J., Kandel, S., Mamani, U., & Cheng, K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.04.003 · Cited by 159 · see citing works
Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies
Baig, M. H., Ahmad, K., Moon, J. S., Park, S.-Y., Ho Lim, J., Chun, H. J., Qadri, A. F., Hwang, Y. C., Jan, A. T., Ahmad, S. S., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.876078 · Cited by 135 · see citing works
AI is a viable alternative to high throughput screening: a 318-target study
Program, T. A. A., Wallach, I., Bernard, D., Nguyen, K. T., Ho, G., Morrison, A., Stecuła, A., Rosnik, A. M., O’Sullivan, A. M., Davtyan, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-54655-z · Cited by 137 · see citing works
AlphaFold2 protein structure prediction: Implications for drug discovery
Borkakoti, N., & Thornton, J. M. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102526 · Cited by 137 · see citing works
Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives
Li, J.-H., Gong, C., Zhou, H.-T., Liu, J., Xia, X., Ha, W., Jiang, Y.-Z., Liu, Q.-X., & Xiong, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105489 · Cited by 108 · see citing works
AI-Based Protein Structure Prediction in Drug Discovery: Impacts and Challenges
Schauperl, M., & Denny, R. A. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00026 · Cited by 122 · see citing works
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H. W., Arora, S., Kumar, R., & Gavande, N. S. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01707-5 · Cited by 115 · see citing works
Ohta, A., Tanada, M., Shinohara, S., Morita, Y., Nakano, K., Yamagishi, Y., Takano, R., Kariyuki, S., Iida, T., Matsuo, A., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c07145 · Cited by 114 · see citing works
Hashemi, Z. S., Zarei, M., Fath, M. K., Ganji, M., Farahani, M. S., Afsharnouri, F., Pourzardosht, N., Khalesi, B., Jahangiri, A., Rahbar, M. R., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.669431 · Cited by 101 · see citing works
An overview of kinase downregulators and recent advances in discovery approaches
Wang, B., Wu, H., Hu, C., Wang, H., Liu, J., Wang, W., & Liu, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00826-7 · Cited by 91 · see citing works
Recent Advances in Deep Learning for Protein-Protein Interaction Analysis: A Comprehensive Review
Lee, M. (2023) · Molecules · doi:10.3390/molecules28135169 · Cited by 93 · see citing works
Zhang, Y., Li, Y., Quan, Z., Xiao, P., & Duan, J. (2024) · Antioxidants · doi:10.3390/antiox13020203 · Cited by 92 · see citing works
Targeting Biomolecular Condensation and Protein Aggregation against Cancer
Silva, J. L., Foguel, D., Ferreira, V. F., Vieira, T. C. R. G., Marques, M. A., Ferretti, G. D. S., Outeiro, T. F., Cordeiro, Y., & de Oliveira, G. A. P. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00131 · Cited by 85 · see citing works
Romero‐Molina, S., Ruiz‐Blanco, Y. B., Mieres‐Pérez, J., Harms, M., Münch, J., Ehrmann, M., & Sánchez‐García, E. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00020 · Cited by 86 · see citing works
Recent advances in predicting and modeling protein–protein interactions
Durham, J., Zhang, J., Humphreys, I. R., Pei, J., & Cong, Q. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2023.03.003 · Cited by 80 · see citing works
Machine learning solutions for predicting protein–protein interactions
Casadio, R., Martelli, P. L., & Savojardo, C. (2022) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1618 · Cited by 80 · see citing works
Enhanced Protein-Protein Interaction Discovery via AlphaFold-MultimerPreprint
Kim, A., Hu, Y., Comjean, A., Rodiger, J., Mohr, S. E., & Perrimon, N. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.19.580970 · Cited by 76 · see citing works
Kruse, T., Benz, C., Garvanska, D. H., Lindqvist, R., Mihalič, F., Coscia, F., Inturi, R., Sayadi, A., Simonetti, L., Nilsson, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26498-z · Cited by 75 · see citing works
Selection of Nucleotide-Encoded Mass Libraries of Macrocyclic Peptides for Inaccessible Drug Targets
Colas, K., Bindl, D., & Suga, H. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00422 · Cited by 77 · see citing works
μMap Photoproximity Labeling Enables Small Molecule Binding Site Mapping
Huth, S. W., Oakley, J. V., Seath, C. P., Geri, J. B., Trowbridge, A., Parker, D. L., Rodriguez‐Rivera, F. P., Schwaid, A. G., Ramil, C. P., Ryu, K. A., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c03325 · Cited by 73 · see citing works
Lysine-Targeted Reversible Covalent Ligand Discovery for Proteins via Phage Display
Zheng, M., Chen, F., Li, K., Reja, R. M., Hæffner, F., & Gao, J. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c07375 · Cited by 71 · see citing works
Bharmoria, P., Tietze, A. A., Mondal, D., Kang, T. S., Kumar, A., & Freire, M. G. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00551 · Cited by 71 · see citing works
New Insights into the Structure and Function of Class B1 GPCRs
Cary, B. P., Zhang, X., Cao, J., Johnson, R. M., Piper, S., Gerrard, E. J., Wootten, D. L., & Sexton, P. M. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac033 · Cited by 69 · see citing works
Xie, R., Gu, Y., Li, M., Li, L., Yang, Y., Sun, Y., Zhou, B., Liu, T., Wang, S., Liu, W., et al. (2024) · Microbiome · doi:10.1186/s40168-023-01722-8 · Cited by 69 · see citing works
Mapping, Structure and Modulation of PPI
Martino, E., Chiarugi, S., Margheriti, F., & Garau, G. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.718405 · Cited by 49 · see citing works
You, K. S., Yi, Y. W., Cho, J., Park, J., & Seong, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14060589 · Cited by 64 · see citing works
Raies, A. B., Tulodziecka, E., Stainer, J., Middleton, L., Dhindsa, R. S., Hill, P., Engkvist, O., Harper, A. R., Petrovski, S., & Vitsios, D. (2022) · Communications Biology · doi:10.1038/s42003-022-04245-4 · Cited by 62 · see citing works
Artificial intelligence in peptide-based drug design
Zhai, S., Liu, T., Lin, S., Li, D., Liu, H., Yao, X., & Hou, T. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104300 · Cited by 66 · see citing works
Iyer, R. S., Needham, S. R., Galdadas, I., Davis, B. M., Roberts, S. K., Man, R. C. H., Zanetti-Domingues, L. C., Clarke, D. T., Fruhwirth, G. O., Parker, P. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46284-x · Cited by 58 · see citing works
Studying protein–protein interactions: Latest and most popular approaches
Akbarzadeh, S., Coşkun, Ö., & Günçer, B. (2024) · Journal of Structural Biology · doi:10.1016/j.jsb.2024.108118 · Cited by 58 · see citing works
Pellegrino, N., Güven, A., Gray, K., Shah, P., Kasture, G., Nastke, M.-D., Thakurta, A., Gesta, S., Vishnudas, V. K., Narain, N. R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073480 · Cited by 57 · see citing works
De novo molecular design with deep molecular generative models for PPI inhibitors
Wang, J., Chu, Y., Mao, J., Jeon, H.-N., Jin, H., Zeb, A., Jang, Y., Cho, K., Song, T., & No, K. T. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac285 · Cited by 52 · see citing works
Grand Challenges of Computer-Aided Drug Design: The Road Ahead
Medina‐Franco, J. L. (2021) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2021.728551 · Cited by 57 · see citing works
Structure-based assessment and druggability classification of protein–protein interaction sites
Alzyoud, L., Bryce, R. A., Sorkhy, M. A., Atatreh, N., & Ghattas, M. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-12105-8 · Cited by 51 · see citing works
Wandering beyond small molecules: peptides as allosteric protein modulators
Mannes, M., Martin, C., Menet, C. J., & Ballet, S. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.10.011 · Cited by 49 · see citing works
Challenges in Discovering Drugs That Target the Protein–Protein Interactions of Disordered Proteins
Olah, J., Szénási, T., Lehotzky, A., Norris, V., & Ovádi, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031550 · Cited by 43 · see citing works
Machine Learning for Causal Inference in Biological Networks: Perspectives of This Challenge
Lecca, P. (2021) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2021.746712 · Cited by 48 · see citing works
Konstantinidou, M., Visser, E. J., Vandenboorn, E., Chen, S., Jaishankar, P., Overmans, M., Dutta, S., Neitz, R. J., Renslo, A. R., Ottmann, C., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c05161 · Cited by 47 · see citing works
Current status of community resources and priorities for weed genomics research
Montgomery, J. S., Morran, S., MacGregor, D. R., McElroy, J. S., Neve, P., Neto, C., Vila‐Aiub, M. M., Sandoval, M. V., Menéndez, A. I., Kreiner, J. M., et al. (2024) · Genome biology · doi:10.1186/s13059-024-03274-y · Cited by 47 · see citing works
Magnez, R., Bailly, C., & Thuru, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147672 · Cited by 46 · see citing works
Park, S., Kim, J. Y., Jang, G.-B., Choi, J.-H., Kim, J., Lee, C.-J., Lee, S., Baek, J., Park, K., Kim, J., et al. (2021) · Theranostics · doi:10.7150/thno.63446 · Cited by 46 · see citing works
Wu, X., Lin, H., Bai, R., & Duan, H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116262 · Cited by 47 · see citing works
New Approaches to Herbicide and Bioherbicide Discovery
Duke, S. O., Twitty, A., Baker, C. S., Sands, D. C., Boddy, L. G., Travaini, M. L., Sosa, G. M., Polidore, A. L. A., Jhala, A. J., Kloeber, J. M., et al. (2024) · Weed Science · doi:10.1017/wsc.2024.54 · Cited by 44 · see citing works
Scanning Protein Surfaces with DNA‐Encoded Libraries
Kunig, V. B. K., Potowski, M., Škopić, M. K., & Brunschweiger, A. (2020) · ChemMedChem · doi:10.1002/cmdc.202000869 · Cited by 43 · see citing works
Pei, H., Guo, W., Peng, Y., Xiong, H., & Chen, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21886 · Cited by 45 · see citing works
Bose, M., Quipildor, G. F., Ehrlich, M. E., & Salton, S. R. (2022) · Cells · doi:10.3390/cells11223629 · Cited by 44 · see citing works
Zhou, Z., Li, X., Yang, G., Wang, J., Li, B., Huang, Y., Yan, J., & Tao, K. (2023) · Theranostics · doi:10.7150/thno.83377 · Cited by 44 · see citing works
SaLT&PepPr is an interface-predicting language model for designing peptide-guided protein degraders
Brixi, G., Ye, T., Hong, L., Wang, T., Monticello, C., Lopez‐Barbosa, N., Vincoff, S., Yudistyra, V., Zhao, L., Haarer, E. L., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05464-z · Cited by 41 · see citing works
Taechalertpaisarn, J., Ono, S., Okada, O., Johnstone, T. C., & Lokey, R. S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00010 · Cited by 43 · see citing works
Protein–protein interaction prediction methods: from docking-based to AI-based approaches
Tsuchiya, Y., Yamamori, Y., & Tomii, K. (2022) · Biophysical Reviews · doi:10.1007/s12551-022-01032-7 · Cited by 44 · see citing works
Ramirez-Velez, I., & Belardi, B. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114905 · Cited by 45 · see citing works
Keeping the Balance: GABAB Receptors in the Developing Brain and Beyond
Bassetti, D. (2022) · Brain Sciences · doi:10.3390/brainsci12040419 · Cited by 43 · see citing works
Li, S., Wu, S., Wang, L., Li, F., Jiang, H., & Bai, F. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102344 · Cited by 42 · see citing works
A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis
Ayoub, N., Gedeon, A., & Munier‐Lehmann, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1329011 · Cited by 42 · see citing works
Understanding the function and regulation of Sox2 for its therapeutic potential in breast cancer
Dey, A., Kundu, M., Das, S., Jena, B. C., & Mandal, M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188692 · Cited by 41 · see citing works
From Concepts to Inhibitors: A Blueprint for Targeting Protein–Protein Interactions
Hong, S. H., Nguyễn, T. T., Ongkingco, J. F., Nazzaro, A., & Arora, P. S. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00046 · Cited by 44 · see citing works
Monti, A., Vitagliano, L., Caporale, A., Ruvo, M., & Doti, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097842 · Cited by 40 · see citing works
Lucero, B., Francisco, K. R., Liu, L. J., Caffrey, C. R., & Ballatore, C. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.04.007 · Cited by 39 · see citing works
The amino acid transporter SLC7A11 expression in breast cancer
Nath, P., Alfarsi, L. H., Ansari, R. E., Masisi, B. K., Erkan, B., Fakroun, A., Ellis, I. O., Rakha, E. A., & Green, A. R. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2291855 · Cited by 41 · see citing works
Raghu, M. S., Kumar, K. Y., Veena, K., Kumar, C. B. P., Almalki, A. S., Mani, G., Alasmary, F. A., & Prashanth, M. K. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131857 · Cited by 39 · see citing works
Towards design of drugs and delivery systems with the Martini coarse-grained model
Kjølbye, L. R., Pereira, G. P., Bartocci, A., Pannuzzo, M., Albani, S., Marchetto, A., Jiménez‐García, B., Martin, J., Rossetti, G., Cecchini, M., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16 · Cited by 39 · see citing works
ProtInteract: A deep learning framework for predicting protein–protein interactions
Soleymani, F., Paquet, E., Viktor, H. L., Michalowski, W. J., & Spinello, D. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.01.028 · Cited by 39 · see citing works
Cheng, J., Zhou, J., Kong, L., Wang, H., Zhang, Y., Wang, X., Liu, G., & Chu, Q. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00487b · Cited by 39 · see citing works
Kumar, V., Lakshman, P. K. C., Prasad, T. K., Manjunath, K., Bairy, S. G., Vasu, A. S., Ganavi, B., Jasti, S., & Kamariah, N. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23864 · Cited by 40 · see citing works
Monteleone, S., Fedorov, D. G., Townsend‐Nicholson, A., Southey, M. W. Y., Bodkin, M. J., & Heifetz, A. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00457 · Cited by 38 · see citing works
Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity
Golkowski, M. G., Lius, A., Sapre, T., Lau, H.-T., Moreno, T., Maly, D. J., & Ong, S. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.01.015 · Cited by 37 · see citing works
Wolter, M., Valenti, D., Cossar, P. J., Hristeva, S., Levy, L. M., Genski, T., Hoffmann, T., Brunsveld, L., Tzalis, D., & Ottmann, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00401 · Cited by 37 · see citing works
Liao, J., Madahar, V., Dang, R., & Jiang, L. (2021) · Molecules · doi:10.3390/molecules26216339 · Cited by 36 · see citing works
Somsen, B. A., Cossar, P. J., Arkin, M. R., Brunsveld, L., & Ottmann, C. (2024) · ChemBioChem · doi:10.1002/cbic.202400214 · Cited by 36 · see citing works
Lin, C. X., Yang, K., Li, P. C., Gao, L. T., Aziz, Y., Li, J. H., Miyatake, H., Ito, Y., & Chen, Y. M. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114089 · Cited by 36 · see citing works
Li, T., Liu, X., Qian, H., Zhang, S., Hou, Y., Zhang, Y., Luo, G., Zhu, X., Tao, Y., Fan, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51197-w · Cited by 37 · see citing works
Mechanisms Applied by Protein Inhibitors to Inhibit Cysteine Proteases
Tušar, L., Usenik, A., Turk, B., & Türk, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22030997 · Cited by 35 · see citing works
Component stabilizing mechanism of membrane-separated hydrolysates on frozen surimi
Zhai, Y., Peng, W., Luo, W., Wu, J., Liu, Y., Wang, F., Li, X., Yu, J., & Wang, S. (2023) · Food Chemistry · doi:10.1016/j.foodchem.2023.137114 · Cited by 35 · see citing works
Zheng, J., Chen, D., Xu, J., Ding, X., Wu, Y., Shen, H. C., & Tan, X. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128229 · Cited by 35 · see citing works
Artificial intelligence based methods for hot spot prediction
Ovek, D., Abali, Z., Zeylan, M. E., Keskin, Ö., Gürsoy, A., & Tunçbağ, N. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.11.003 · Cited by 36 · see citing works
Camps-Fajol, C., Cavero, D., Minguillón, J., & Surrallés, J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107544 · Cited by 35 · see citing works
Yoshida, S., Uehara, S., Kondo, N., Takahashi, Y., Yamamoto, S., Kameda, A., Kawagoe, S., Inoue, N., Yamada, M., Yoshimura, N., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00919 · Cited by 33 · see citing works
Targeting the Mitochondrial Protein VDAC1 as a Potential Therapeutic Strategy in ALS
Shteinfer‐Kuzmine, A., Argueti-Ostrovsky, S., Leyton-Jaimes, M. F., Anand, U., Abu‐Hamad, S., Zalk, R., Shoshan‐Barmatz, V., & Israelson, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179946 · Cited by 33 · see citing works
Mapping oncogenic protein interactions for precision medicine
Tabar, M. S., Francis, H., Yeo, D., Bailey, C. G., & Rasko, J. E. J. (2022) · International Journal of Cancer · doi:10.1002/ijc.33954 · Cited by 30 · see citing works
Vijh, D., Imam, M. A., Haque, M. M. U., Das, S., Islam, A., & Malik, M. Z. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01160-3 · Cited by 32 · see citing works
Regenerative therapies as a potential treatment of erectile dysfunction
Chung, D. Y., Ryu, J., & Yin, G. N. (2023) · Korean journal of urology · doi:10.4111/icu.20230104 · Cited by 32 · see citing works
MARK2/MARK3 Kinases Are Catalytic Codependencies of YAP/TAZ in Human Cancer
Klingbeil, O., Skopelitis, D. S., Tonelli, C., Yoshimoto, T., Alpsoy, A., Panepinto, M. C., Minicozzi, F., Merrill, J. R., Cafiero, A. M., Aggarwal, D., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1529 · Cited by 31 · see citing works
Solubility-Aware Protein Binding Peptide Design Using AlphaFold
Kosugi, T., & Ohue, M. (2022) · Biomedicines · doi:10.3390/biomedicines10071626 · Cited by 33 · see citing works
de Araujo, A. D., Lim, J., Wu, K., Hoang, H. N., Nguyen, H. T., & Fairlie, D. P. (2022) · RSC Chemical Biology · doi:10.1039/d1cb00231g · Cited by 32 · see citing works
Cui, J., Ogasawara, Y., Kurata, I., Matoba, K., Fujioka, Y., Noda, N. N., Shibasaki, M., & Watanabe, T. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c07648 · Cited by 32 · see citing works
Albu, A.-I., Bocicor, M.-I., & Czibula, G. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106526 · Cited by 34 · see citing works
Selective fluorescent labeling of cellular proteins and its biological applications.
Choi, J., Kim, S., Kang, O.-Y., Choi, S. Y., Ji, Y. H., Lee, H. S., & Shin, I. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00094c · Cited by 12 · see citing works
Rapid Development of Analytical Methods for Evaluating Pandemic Vaccines: A Covid-19 Perspective
Baldwin, J., Piplani, S., Sakala, I. G., Honda‐Okubo, Y., Li, L., & Petrovsky, N. (2021) · Bioanalysis · doi:10.4155/bio-2021-0096 · Cited by 31 · see citing works
- Authors
- Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J.
- Affiliations
- University of Electronic Science and Technology of China (CN)
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (CN)
- Sichuan University (CN)
- University of Miami (US)
- Chengdu University of Traditional Chinese Medicine (CN)
- Corresponding author
- Peng, Cheng
- Tong, Rongsheng
- Shi, Jianyou
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2020-09-23
- Volume
- 5
- Issue
- 1
- Pages
- 213-213
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC7511340
- OpenAlex
- W3087769169
- Cited by
- 891
- References
- 272
- Citations by year
- 2026: 125 · 2025: 195 · 2024: 192 · 2023: 159 · 2022: 141 · 2021: 75 · 2020: 1 · 2013: 1
- FWCI
- 9.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Chengdu Science and Technology Bureau (No. 2015-HM01-00463-SF)
- State Administration of Traditional Chinese Medicine of the People’ Republic of China (JDZX2015210)
- the Open Research Fund of Chengdu University of Traditional Chinese Medicine Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China
- the Key Research and Development Program of Science and Technology Department of Sichuan Provinc
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, PPI inhibitors, drug discovery, small molecules, peptides, immunoglobulins, cancer, infectious diseases, neurodegenerative diseases, clinical trials
- MeSH terms
- Humans, Infections, Neoplasms, Drug Delivery Systems, Neurodegenerative Diseases, Drug Discovery, Protein Interaction Maps
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
